AVLN (Avalyn Pharma) Non Operating Income: $ Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AVLN Avalyn Pharma Inc AVLN
12 GF Score
Price $31.35
View Full Analysis

What is Avalyn Pharma Non Operating Income?

Avalyn Pharma AVLN -5.63% 12 Non Operating Income is $ Mil as of Jun. 2026. GuruFocus rates AVLN with a GF Score™ of 12/100.

Non Operating Income is income or expense that comes from miscellaneous sources. Avalyn Pharma's Non Operating Income for the three months ended in Jun. 2026 was $ Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was $ Mil.

Avalyn Pharma Non Operating Income Related Terms

Avalyn Pharma Non Operating Income Historical Data

* Premium members only.

The historical data trend for Avalyn Pharma's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avalyn Pharma Non Operating Income Chart

Avalyn Pharma Annual Data
Trend Dec24 Dec25
Non Operating Income
- -

Avalyn Pharma Quarterly Data
Mar25 Jun25 Mar26 Jun26
Non Operating Income - - - -
AVLN
12GF Score
Avalyn Pharma Inc AVLN
Non Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avalyn Pharma Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $ Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of $ Mil mean?
Avalyn Pharma (AVLN) has a Non Operating Income of $ Mil as of Jun. 2026. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Avalyn Pharma and its competitors.
Is Avalyn Pharma's Non Operating Income too high?
Avalyn Pharma's current Non Operating Income is $ Mil. Overall, Avalyn Pharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Avalyn Pharma's Non Operating Income compare to LBRX and LTGO?
Avalyn Pharma's Non Operating Income of $ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Biotechnology company?
A good Non Operating Income depends on the Biotechnology industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Avalyn Pharma and its competitors. Avalyn Pharma's current Non Operating Income is $ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avalyn Pharma stock overvalued right now?
Avalyn Pharma (AVLN) has a current Non Operating Income of $ Mil. The current Non Operating Income is $ Mil. Avalyn Pharma's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For Avalyn Pharma (AVLN), the current Non Operating Income is $ Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avalyn Pharma Business Description

Address 105 W First Street, Boston, MA, USA, 02127
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
12GF Score

Get the complete analysis for AVLN

Non Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.35
Price